Treatment satisfaction in patients with type 2 diabetes is significantly improved with liraglutide, the once-daily GLP-1 analogue versus sitagliptin, both combined with metformin

被引：0
|
作者：
Montanya Mias, E. [1 ]
Cuddihy, R. [2 ]
Pratley, R. [3 ]
Hammer, M. [4 ]
Thomsen, A. [4 ]
Davies, M. J. [5 ]
机构：
[1] IDIBELL Hosp Univ Bellvitge, Barcelona, Spain
[2] Int Diabet Ctr, Minneapolis, MN USA
[3] Univ Vermont, Burlington, VT 05405 USA
[4] Novo Nordisk AS, Soborg, Denmark
[5] Univ Leicester, Leicester LE1 7RH, Leics, England
来源：
DIABETOLOGIA | 2010年 / 53卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
832
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin
    Kapitza, C.
    Forst, T.
    Coester, H. -V.
    Poitiers, F.
    Ruus, P.
    Hincelin-Mery, A.
    DIABETES OBESITY & METABOLISM, 2013, 15 (07): : 642 - 649
  • [32] The impact of GLP-1 analogue liraglutide on type 2 diabetes patients with and without insulin therapy
    Haq, Z.
    Reidy, Y.
    Dempsey, M.
    Reidy, C.
    Keogh, A. M.
    Hoashi, S.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2011, 180 : S491 - S492
  • [33] Liraglutide: A Once-Daily Incretin Mimetic for the Treatment of Type 2 Diabetes Mellitus
    Neumiller, Joshua J.
    Campbell, R. Keith
    ANNALS OF PHARMACOTHERAPY, 2009, 43 (09) : 1433 - 1444
  • [34] Liraglutide, a once-daily human GLP-1 analog, in type 2 diabetes provides similar glycemic control with reduced body weight compared with glimepiride when added to metformin
    Nauck, Michael A.
    Frid, Anders
    Hermansen, Kjeld
    Shah, Nalini S.
    Tankova, Tsvetalina
    Mitha, Ismail H.
    During, Maria
    Zdravkovic, Milan
    Matthews, David
    DIABETES, 2008, 57 : A150 - A150
  • [35] The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients
    Anne Flint
    Christoph Kapitza
    Charlotte Hindsberger
    Milan Zdravkovic
    Advances in Therapy, 2011, 28 : 213 - 226
  • [36] Once daily dosing of the long acting GLP-1 analogue liraglutide significantly improves glycaemic control by reducing both fasting and post-prandial glucose levels in Japanese subjects with type 2 diabetes
    Seino, Yutaka
    Kaku, Kohei
    Nishijima, Keiji
    Rasmussen, Mads F.
    Zdravkovic, Milan
    Kristensen, Peter
    DIABETES, 2007, 56 : A138 - A139
  • [37] The Once-Daily Human Glucagon-Like Peptide-1 (GLP-1) Analog Liraglutide Improves Postprandial Glucose Levels in Type 2 Diabetes Patients
    Flint, Anne
    Kapitza, Christoph
    Hindsberger, Charlotte
    Zdravkovic, Milan
    ADVANCES IN THERAPY, 2011, 28 (03) : 213 - 226
  • [38] Liraglutide, the once-daily human GLP-1 analogue, has a protracted profile based on both delayed absoprtion and a long plasma half-life
    Knudsen, L. Bjerre
    Nielsen, P. F.
    Steensgaard, D. B.
    Bloch, P.
    Lau, J.
    Agersoe, H.
    DIABETOLOGIA, 2009, 52 : S305 - S306
  • [39] Effects of Sitagliptin and Metformin Treatment on GLP-1 Responses to Oral Glucose and on the Incretin Effect in Patients With Type 2 Diabetes
    Vardarli, Irfan
    Arndt, Elisabeth
    Deacon, Carolyn F.
    Holst, Jens J.
    Kothe, Lars D.
    Nauck, Michael A.
    DIABETES, 2012, 61 : A17 - A17
  • [40] Sitagliptin and Metformin Increase Active GLP-1 by Complementary Mechanisms in Treatment-Naive Patients with Type 2 Diabetes
    Migoya, Elizabeth
    Miller, Jutta
    Luo, Wen-Lin
    O'Neill, Edward
    Morrow, Linda
    Gutierrez, Maria
    Stoch, Aubrey
    Wagner, John A.
    DIABETES, 2010, 59 : A156 - A156
12345